As clinicians recognize the importance of controlling a full spectrum of comorbidities linked to cardiometabolic events, David Calabrese, RPh, MHP, highlights the benefits of new single-agents and explains how these options treat multiple components.
Yehuda Handelsman, MD, FACP, FACE, FNLA, explains that as different formulations with different delivery systems evolve, they offer additional benefits to clinicians and patients.
For example, Dr Handelsman points out that when delivering insulin for the treatment of diabetes, new agents can be administered through a pen option instead of a syringe. Additionally, he explains that many new agents are long-acting, offering more convenience to patients.
Concerned about the differences in cost between older and newer agents, Kenneth L. Schaecher, MD, FACP, CPC, questions Dr Handelsman about the significance of utilizing the pen rather than
the syringe as a delivery option.
Dr Handelsman explains that although the pen option is a more expensive delivery option, the accuracy of the pen has been acknowledged in many settings, including the hospital setting, and has helped improve glycemic goals.
Bridging the Vaccination Gap: Insights on Global Immunization Challenges
July 30th 2024On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.
Listen
Despite Record ACA Enrollment, Report Reveals Underinsured Americans Are in Crisis
November 21st 2024Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access to and affordability of health care.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Intensive Blood Pressure Regimen Lowers CVD Risk for People With Diabetes
November 19th 2024Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.
Read More
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More